ReviewVirology journal2026
World free HIV: the novel therapeutic approaches for eliminating latent HIV infection.
Review in Virology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiretroviral therapy (ART) is an intervention aimed at preventing the development and spread of HIV. The persistence of proviruses in the CD4 + memory T cells, which are transcriptionally inactive and other drug-resistant reservoirs, makes treatment of chronic HIV-1 infection through pharmacological means complex. The major measures to deal with the disease involve reactivating the inactive viruses then clearing them off by using virus-specific cytotoxic effect and also by host immune responses. Broadcast screening and mechanism-based techniques have revealed a huge number of medications that can reactivate latent infections. The review carried out relies on Cochrane Central Register of Controlled Trials (CENTRAL), PubMed (NCBI), Scopus (Elsevier), and Web of Science (Clarivate) databases. Some of the therapeutic alternatives mentioned are Shock and Kill, cytokines, chemokines, histone methyl transferase inhibitor, immunotherapy, protein kinase C activator, P-TEFb activator, and uncharacterized ones like vorinostat and disulfiram. These techniques have proven to be effective using models working with CD4 + T lymphocytes and dormant cell lines in HIV-1 infected patients. The given paper includes an in-depth evaluation of the existing situation in the field and its hardships.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.